Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Allogeneic CAR Cell Therapy—More Than a Pipe Dream
Kenneth J. Caldwell, Stephen Gottschalk, Aimee C. Talleur
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 99

Showing 1-25 of 99 citing articles:

Advances in Universal CAR-T Cell Therapy
Haolong Lin, Jiali Cheng, Wei Mu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 133
CAR-T: What Is Next?
Yi‐Ju Chen, Bams Abila, Yasser Mostafa Kamel
Cancers (2023) Vol. 15, Iss. 3, pp. 663-663
Open Access | Times Cited: 127
Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy
Yiming Xia, Shunli Fu, Qingping Ma, et al.
Nano-Micro Letters (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 48
Successes and challenges in clinical gene therapy
Donald B. Kohn, Yvonne Y. Chen, Melissa J. Spencer
Gene Therapy (2023) Vol. 30, Iss. 10-11, pp. 738-746
Open Access | Times Cited: 44
CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
Kaveh Hadiloo, Safa Tahmasebi, Abdolreza Esmaeilzadeh
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 40
Engineering immune-evasive allogeneic cellular immunotherapies
Karen E. Martin, Quirin Hammer, Karlo Perica, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 9, pp. 680-693
Closed Access | Times Cited: 13
The next wave of cellular immunotherapies in pancreatic cancer
Dannel Yeo, Caroline Giardina, Payal Saxena, et al.
Molecular Therapy — Oncolytics (2022) Vol. 24, pp. 561-576
Open Access | Times Cited: 58
Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
Yang Zhou, Miao Li, Kuangyi Zhou, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2266-2266
Open Access | Times Cited: 40
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
Marisa K. Kilgour, Donald Bastin, Seung‐Hwan Lee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 32
Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation
Ratchapong Netsrithong, Laura García-Pérez, Maria Themeli
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 10
Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Ιωάννα Αγγελετοπούλου, Maria Kalafateli, Christos Triantos
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2631-2631
Open Access | Times Cited: 8
Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma
Qizhong Lu, Donghui Yang, Hexian Li, et al.
Cancer Letters (2024) Vol. 585, pp. 216660-216660
Closed Access | Times Cited: 6
Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture
Yan-Ruide Li, Kuangyi Zhou, Derek Lee, et al.
Nature Protocols (2025)
Closed Access
Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
Franziska Brauneck, Elisa Seubert, Jasmin Wellbrock, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12919-12919
Open Access | Times Cited: 40
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
Piotr Celichowski, Marcello Turi, Sandra Charvátová, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 19
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Christina Chen, Xin Liu, Che‐Yu Chang, et al.
Genes (2023) Vol. 14, Iss. 5, pp. 1008-1008
Open Access | Times Cited: 18
Molecular imaging of tumour‐associated pathological biomarkers with smart nanoprobe: From “Seeing” to “Measuring”
Peisen Zhang, Wenyue Li, Chuang Liu, et al.
Exploration (2023) Vol. 3, Iss. 6
Open Access | Times Cited: 18
Umbilical cord blood derived cellular therapy: advances in clinical development
Jiasheng Wang, Leland Metheny
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
Remuneration of donors for cell and gene therapies: an update on the principles and perspective of the World Marrow Donor Association
Lina Hamad, Salmah Mahmood Ahmed, Eefke van Eerden, et al.
Bone Marrow Transplantation (2024) Vol. 59, Iss. 5, pp. 580-586
Open Access | Times Cited: 4
Stealth transgenes enable CAR-T cells to evade host immune responses
Korneel Grauwet, Trisha R. Berger, Michael C. Kann, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 5, pp. e008417-e008417
Open Access | Times Cited: 4
Allogeneic “Off-the-Shelf” CAR T Cells: Challenges and Advances
Sophia Chen, Marcel R.M. van den Brink
Best Practice & Research Clinical Haematology (2024) Vol. 37, Iss. 3, pp. 101566-101566
Closed Access | Times Cited: 4
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
Praveen Ramakrishnan Geethakumari, Dheepthi P. Ramasamy, Bhagirathbhai Dholaria, et al.
Current Hematologic Malignancy Reports (2021) Vol. 16, Iss. 4, pp. 345-356
Open Access | Times Cited: 36
Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
Alejandrina Hernández-López, Mario A. Téllez-González, Paul Mondragón‐Terán, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 35
Implementing Logic Gates for Safer Immunotherapy of Cancer
Mohammed Azharuddin Savanur, Hadas Weinstein-Marom, Gideon Gross
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 33
Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
Sònia Guedan, Maik Luu, Delphine Ammar, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 5, pp. e003487-e003487
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top